You are here

  • Home
  • Archive
  • Volume 9, Issue 8
  • Self-assembly nanovaccine containing TLR7/8 agonist and STAT3 inhibitor enhances tumor immunotherapy by augmenting tumor-specific immune response

Article metrics

Article menu
XML
Clinical/translational cancer immunotherapy
Original research
Self-assembly nanovaccine containing TLR7/8 agonist and STAT3 inhibitor enhances tumor immunotherapy by augmenting tumor-specific immune response

 

Online download statistics by month:

Online download statistics by month: August 2021 to July 2025

AbstractFullPdf
Aug 202120520578
Sep 2021432433213
Oct 202117817893
Nov 202115115269
Dec 202111711966
Jan 2022929362
Feb 2022777761
Mar 202210610752
Apr 202211413270
May 2022929564
Jun 2022929642
Jul 2022869144
Aug 202213513664
Sep 202215816273
Oct 202217117358
Nov 202210210574
Dec 2022404036
Jan 2023646542
Feb 202310310351
Mar 2023777857
Apr 2023767852
May 2023464642
Jun 2023616139
Jul 2023939451
Aug 2023595942
Sep 2023696948
Oct 2023475039
Nov 2023696941
Dec 2023595943
Jan 2024697144
Feb 2024515133
Mar 202410210280
Apr 2024757757
May 2024747655
Jun 2024585929
Jul 2024777936
Aug 2024494828
Sep 20244343516
Oct 2024444534
Nov 2024586338
Dec 2024767849
Jan 2025687045
Feb 202514114161
Mar 2025555835
Apr 2025787955
May 2025656660
Jun 2025303421
Jul 2025110
Total438544663042